Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ependymoma × Bevacizumab × Clear all

Phase

Status

Completed 6 Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 59 Carcinoma, Hepatocellular 37 Ovarian Neoplasms 36 Carcinoma, Non-Small-Cell Lung 24 Neoplasms 18 Fallopian Tube Neoplasms 15 Breast Neoplasms 14 Lung Neoplasms 12 Endometrial Neoplasms 11 Uterine Cervical Neoplasms 9 Triple Negative Breast Neoplasms 9 Liver Neoplasms 9 Glioblastoma 9 Colonic Neoplasms 9 Rectal Neoplasms 8 Neoplasm Metastasis 8 Brain Neoplasms 8 Stomach Neoplasms 7 Colorectal Cancer Metastatic 7 Advanced Solid Tumors 7 Pancreatic Neoplasms 5 Melanoma 5 Carcinoma, Renal Cell 5 Carcinoma, Ovarian Epithelial 5 Solid Tumor 4 Recurrence 4 Meningeal Carcinomatosis 4 Glioma 4 Biliary Tract Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3

Interventions

Temozolomide 2 ONC206 2 Etoposide 2 Cyclophosphamide 2 lutetium Lu 177 dotatate 1 ibrutinib 1 fenofibric acid 1 etoposide phosphate 1 Thalidomide 1 Restraint, Physical 1 Radiotherapy 1 Radiation 1 Magnetic Resonance Spectroscopy 1 Linear Energy Transfer 1 Irinotecan 1 Elasticity Imaging Techniques 1 Cytarabine 1 Celecoxib 1 Bevacizumab 1 Automobiles 1 1-methyltryptophan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡